Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies. The company applies proprietary formulations to approved pharmaceutical compounds to improve efficacy, reduce side effects, and enhance patient compliance. Its three clinical-stage drug candidates are GTx-104 (IV nimodipine for aSAH), GTx-102 (for ataxia-telangiectasia), and GTx-101 (topical bupivacaine for postherpetic neuralgia), all holding FDA Orphan Drug Designation.
Q2 FY2026 — expected 2026-09-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-06-23 | 2025-03-31 | 0001140361-25-023259 | EDGAR | 61K words |
| 2024-06-21 | 2024-03-31 | 0000950170-24-075875 | EDGAR | 74K words |
| 2023-06-23 | 2023-03-31 | 0000950170-23-029498 | EDGAR | — |
| 2022-06-21 | 2022-03-31 | 0000950170-22-011842 | EDGAR | — |
| 2021-06-22 | 2021-03-31 | 0001171843-21-004462 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0001171843-20-004613 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001140361-26-032632 | EDGAR | 18K words |
| 2026-02-12 | 2025-12-31 | 0001140361-26-004924 | EDGAR | 23K words |
| 2025-11-13 | 2025-09-30 | 0001140361-25-041804 | EDGAR | 24K words |
| 2025-08-12 | 2025-06-30 | 0001140361-25-030398 | EDGAR | 19K words |
| 2025-02-13 | 2024-12-31 | 0001140361-25-004153 | EDGAR | 24K words |
| 2024-11-13 | 2024-09-30 | 0001140361-24-046312 | EDGAR | 23K words |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094348 | EDGAR | 19K words |
| 2024-02-12 | 2023-12-31 | 0000950170-24-013566 | EDGAR | 24K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062437 | EDGAR | 25K words |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041595 | EDGAR | 22K words |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002695 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024666 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-18 | 0001140361-26-037114 | EDGAR | 1K words |
| 2026-08-13 | 0001140361-26-032644 | EDGAR | 3K words |
| 2026-08-06 | 0001140361-26-031671 | EDGAR | 2K words |
| 2026-07-28 | 0001140361-26-029837 | EDGAR | 4K words |
| 2026-02-12 | 0001140361-26-004927 | EDGAR | 4K words |
| 2026-01-12 | 0001140361-26-000995 | EDGAR | 1K words |
| 2025-11-13 | 0001140361-25-041807 | EDGAR | 4K words |
| 2025-10-23 | 0001140361-25-039020 | EDGAR | 1K words |
| 2025-09-18 | 0001140361-25-035337 | EDGAR | 2K words |
| 2025-09-12 | 0001140361-25-034845 | EDGAR | 1K words |
367 total filings indexed. 339 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001444192 |
| Ticker | GRCE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gracetx.com |
| Listed | 2011-04-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GRCE (~200 tokens, structured JSON with cryptographic provenance)